Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.65 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18563482 | 0.89 | FFAR1 (0.67) | FFAR1FFAR4AKR1B1LIPGKEAP1 | |
| SCHEMBL23512360 | 0.89 | FFAR1 (0.62) | FFAR1FFAR4AKR1B1LIPGKEAP1 | |
| SCHEMBL7347912 | 0.85 | FFAR1 (0.69) | FFAR1FFAR4AKR1B1LIPGKEAP1 | |
| SCHEMBL1206832 | 0.85 | KEAP1 (0.61) | FFAR1FFAR4KEAP1 | |
| SCHEMBL29381971 | 0.85 | FFAR1 (0.69) | FFAR1FFAR4AKR1B1LIPGKEAP1 | |
| SCHEMBL15238584 | 0.85 | MCL1 (0.49) | FFAR1MCL1BCL2 | |
| SCHEMBL30671117 | 0.84 | FFAR1 (0.71) | FFAR1FFAR4AKR1B1LIPGKEAP1 | |
| SCHEMBL12646398 | 0.84 | FFAR1 (0.69) | FFAR1FFAR4AKR1B1LIPGKEAP1 | |
| SCHEMBL25146340 | 0.84 | FFAR4 (0.59) | FFAR1FFAR4AKR1B1LIPGMCL1 | |
| SCHEMBL1206798 | 0.82 | L3MBTL1 (0.69) | FFAR1FFAR4KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | PPID, PPIF, PPIL1 | FFAR1 776/4885FFAR4 2102/4885AKR1B1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.